Soleno Therapeutics, Inc. (SLNO) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
203 Redwood Shores Parkway
Redwood City, CA 94065
United States of America (the)
Phone
650 213 8444
Website
Sector
Healthcare
Industry
Biotechnology
Employees
115
First IPO Date
November 13, 2014
| Name | Title | Pay | Year Born |
| Anish Bhatnagar | Chairman, President & CEO | 1.23M | 1970 |
| Kristen Yen | Senior Vice President of Global Clinical Operations and Patient Advocacy | 317,190 | 1969 |
| Kevin Norrett | Chief Business Officer | 487,331 | 1973 |
| Manher A. Joshi | Chief Development Officer | 514,721 | 1968 |
| Patricia C. Hirano | Senior Vice President of Regulatory Affairs | 515,813 | 1966 |
| Jennifer Fulk | Chief Financial Officer | 640,000 | 1977 |
| Meredith Manning | Chief Commercial Officer | 676,588 | 1972 |
| James H. MacKaness | Executive Officer | 734,908 | 1964 |
| Mitchell Nagao | Senior Vice President of Medical Affairs | 0 | N/A |
| Neil Cowen | Senior Vice President of New Product Planning | 0 | N/A |
| Michael Huang | Senior Vice President of Clinical Development | 0 | 1974 |
| Jesse Schumaker | General Counsel | 0 | N/A |
| Dairine Dempsey | Senior Vice President of Europe | 0 | N/A |
| Lauren Budesheim | Senior Vice President of People | 0 | N/A |
Soleno Therapeutics, Inc. (SLNO) operates as a clinical-stage biopharmaceutical company, specializing in the creation and market introduction of groundbreaking treatments for uncommon illnesses. The cornerstone of its therapeutic pipeline is Diazoxide Choline Controlled-Release, a once-daily oral tablet aimed at addressing Prader-Willi Syndrome, currently progressing through an active Phase III clinical evaluation. Established in 1999, the Redwood City, California-headquartered firm adopted its current name, Soleno Therapeutics, Inc., in May 2017, having previously operated as Capnia, Inc.